Kaufmann MR, et al. - Authors assessed cases in the Surveillance, Epidemiology, and End Results (SEER) database with neuroblastoma, NOS; ganglioneuroblastoma; or olfactory neuroblastoma diagnosed from birth to 18 years between 1973 and 2014 to study survival in pediatric neuroblastoma and management in the head and neck vs other sites of the body. They classified the candidates into either head and neck, adrenal, and “other,” based on primary tumor site. The 2- and 5-year disease-specific survival rates were 89% and 84% in the head and neck vs 77% and 65% in the adrenal and 84% and 77% in the “other” cohorts. They noted a higher risk of disease-specific death (DSD) in the adrenal cohort vs the head and neck cohort. They noted a lower risk of DSD among individuals with surgery only vs all other treatments that were studied.